You just read:

BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Apr 12, 2019, 14:08 ET